Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.

Bruce Bostrom(Minnesota West Community & Technical College), Gary R. Erdmann

PubMed

February 1, 1993

Cited by 103

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

|Blood|2002|496

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

|Blood|2003|361

Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia

|New England Journal of Medicine|1987|334

Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications

|The Journal of Pediatrics|1996|294

Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study

|Journal of Clinical Oncology|2009|278